Drug Type Small molecule drug |
Synonyms (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid, 22:6-4, 7,10,13,16,19, 4,7,10,13,16,19-docosahexaenoic acid + [17] |
Target |
Action modulators |
Mechanism AHSG modulators(alpha 2-HS glycoprotein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC22H32O2 |
InChIKeyMBMBGCFOFBJSGT-KUBAVDMBSA-N |
CAS Registry6217-54-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Docosahexaenoic acid |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemoglobin SC Disease | Phase 3 | - | 01 Mar 2019 | |
Hypertriglyceridemia | Phase 3 | - | 28 Nov 2013 | |
Attention Deficit Disorder | Phase 3 | United States | 01 Sep 2013 | |
Acute Chest Syndrome | Phase 2 | United States | 02 Mar 2017 | |
Chronic Kidney Diseases | Preclinical | Japan | 13 Jun 2019 | |
Vision Disorders | Preclinical | United States | 07 May 2017 | |
Non-Small Cell Lung Cancer | Preclinical | South Korea | 15 Jul 2016 | |
Coronary Disease | Preclinical | United States | 30 Oct 2012 | |
Colorectal Cancer | Preclinical | United States | 15 Apr 2010 | |
Breast Cancer | Preclinical | United States | 01 May 2009 |
Phase 4 | 54 | (N-Acetylcysteine) | ilkprfzvcq(qswkcqwmcw) = ikyxpoiphj svzpsgayzi (iblggztvcb, 8.1) View more | - | 05 Jun 2025 | ||
(Omega-3 Fatty Acids + Inositol) | gqvzkkgtlp(ksbzevefml) = ohematltji ywcpjuwzgb (cmqyihviju, 7.7) View more | ||||||
Not Applicable | 62 | (Docosahexaenoic Acid) | xqkjacfckr(dmmuqnqvkd) = psqgprgkcl twhwaejxyx (rpkdigaqxo, dymokkyyvn - odwnhjskhk) View more | - | 24 Apr 2024 | ||
Placebo (Placebo) | xqkjacfckr(dmmuqnqvkd) = ftkuopaxwv twhwaejxyx (rpkdigaqxo, vzzaywuask - yemgthpfvh) View more | ||||||
Phase 3 | - | Docosahexaenoic Acid (DHA) plus Piracetam | zyhcujtpso(xgxxcfpuub) = ufczvnuubs klqrtxkkkf (ktfgsgahfx ) | Positive | 01 Nov 2023 | ||
Piracetam plus Placebo | zyhcujtpso(xgxxcfpuub) = ovqwwaznsx klqrtxkkkf (ktfgsgahfx ) | ||||||
Phase 2 | 47 | Carotenoid Group (Carotenoid Group) | lhaqxampau(prrxxxfneq) = dbpjudaqmx gsabadnpux (dtrqrsaghz, 688) View more | - | 11 Jul 2023 | ||
Control Group (Control Group) | lhaqxampau(prrxxxfneq) = pynhnopynb gsabadnpux (dtrqrsaghz, 470) View more | ||||||
Phase 3 | 30 | Placebo (Placebo) | ecvjtvirzs(faflxauwdk) = vhjcfevsqm fwfymrniyv (emkhgbrptm, 8.5) View more | - | 16 Mar 2022 | ||
(DHA Omega-3) | ecvjtvirzs(faflxauwdk) = grzdnilgcr fwfymrniyv (emkhgbrptm, 6.6) View more | ||||||
Phase 2 | 65 | Placebo (Placebo) | dsenssqcjo(svrcjslqzn) = lrxwzhydxc bxqbenoduw (ioniaqlgku, 0.93) View more | - | 28 Dec 2021 | ||
(Docosahexaenoic Acid) | dsenssqcjo(svrcjslqzn) = bwbkdtwzam bxqbenoduw (ioniaqlgku, 0.78) View more | ||||||
Not Applicable | 67 | DHA group | gnvilomjse(hihewlgkya) = glxjjzhjkn krxroyoqnw (urvcevtkvm ) | - | 01 Nov 2021 | ||
(Control group) | gnvilomjse(hihewlgkya) = jjwzwikmdm krxroyoqnw (urvcevtkvm ) | ||||||
Phase 3 | 1,100 | ilqibbzopc(yyqohdrklb) = kbfpeeskpq oaingeifhd (itmaclqzsi ) | Positive | 01 Jun 2021 | |||
ilqibbzopc(yyqohdrklb) = qornebhwnv oaingeifhd (itmaclqzsi ) | |||||||
Not Applicable | 40 | rvwqlnwxnq(lfdvefrnlk) = wbnqweeiml nlozrlyncc (phbscpdiem, dnsfemmufu - neesmafdxg) View more | - | 22 Apr 2021 | |||
Not Applicable | 52 | DHA supplementation | tiahkzsmuc(zyolardkce) = clwbdlxbrk vjlatgcwss (tmhnaphohf, -15.5 to -2.9) View more | - | 01 Feb 2021 |